Navigation Links
Florida Man Develops Bladder Cancer as Result of Taking Actos, Alleges Lawsuit Filed by Parker Waichman LLP
Date:6/24/2013

New York, NY (PRWEB) June 24, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Florida man who developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23, 2013 in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1236). It is one of thousands of cases that have been filed into the multidistrict litigation (MDL) entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff took Actos to treat his Type 2 diabetes from January 2002 to April 2005, when he was diagnosed with bladder cancer. The lawsuit alleges that his bladder cancer was due to the side effects of Actos. Additionally, the suit alleges that the Defendants knew about the risk of bladder cancer but did not disclose this information to consumers in order to protect financial interests. The Plaintiff alleges that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer and announced that the label would be updated to reflect this risk. This warning was based on an ongoing 10-year study by Kaiser Permanente. (http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm)

Several studies support the link between Actos and bladder cancer. Last May, a study in the British Medical Journal found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal found that patients taking the medication were 22 percent more likely to get bladder cancer. (http://www.bmj.com/content/344/bmj.e3645) (http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102)

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/actos-bladdercancer-claim/06/prweb10859164.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Into Action Drug and Alcohol Treatment Center Donates Tiles to RiseUP Gallery in Miami, Florida
2. Florida Lawmakers Agenda Against the Future of Medical and Recreational Marijuana in Florida May Have Severe Repercussions, as Reported by PotStores.com
3. Key West, Florida Joins Best Halfway House Recovery Network, Helping People Seek Further Recovery from Drug and Alcohol Addiction
4. Nemours Pediatric ENT Performs Minimally Invasive Procedure on South Florida Boy at Wolfson Children’s Hospital in Jacksonville, FL
5. Pensacola, Florida Joins Best Halfway House Recovery Network, Providing Resources for Those Seeking to Further Their Recovery from Drug and Alcohol Addiction
6. Florida Athletes Prepare for National Veteran Wheelchair Games in Tampa
7. Controversial Detox Center Billboard Appearing in South Florida
8. The Women’s Board of Wolfson Children’s Hospital Announces 2013-2014 Florida Forum Lineup
9. US Sports Camps Announces NIKE Baseball Camps to Host Two New Camp Locations in Florida
10. South Florida's Most Popular Dermatologist Dr. Flor Mayoral Launches New Website at MayoralDerm.com
11. US Drug Watchdog Now Urges All Florida Recipients of a Recalled DePuy ASR XL Hip Implant to Call Them Immediately if They Have Not Yet Been Identified by a Law Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending ... the unique opportunity to get hands-on experience in an emergency medical simulation, When ... experience to gain invaluable, real-life medical skills that are critical success in a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
(Date:12/7/2016)... ... 2016 , ... Levels of a protein in the blood associated with heart ... in the journal Radiology. , Heart disease and brain disease exact a major burden ... aging population. Damage to both organs often occurs at a subclinical stage, or before ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016 According to the latest ... Market Study on Multiplex Detection Immunoassay: North America to ... global multiplex detection immunoassay market is expected to witness a CAGR ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
(Date:12/7/2016)... 2016 The global  blood ... of USD 3.9 billion by 2024, based on ... The growth of the market is attributed to ... advancements by the market players. Demand for blood ... donation, rising awareness about transfusion-transmitted diseases, and technological ...
(Date:12/6/2016)... 6, 2016  Alopexx Oncology, LLC announced data from ... fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting ... on B cells as Rituxan and maintains the activities ... also involved in tumor targeting, engagement of the immune ... results of the study (abstract #95954) were presented at ...
Breaking Medicine Technology: